SLS

SELLAS Life Sciences Group, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.33
52-Week Range: $1.39 – $15.88
Market Cap: $2.37B
P/E (TTM): —
EPS (TTM): -0.21
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 17.21
PEG Ratio: —
Return on Equity: -39.63%
Return on Assets: -23.30%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 18.83
Debt/Equity: 0.01
Total Debt: $737.00K
Free Cash Flow: $-16.38M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.23B

SLS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.00M	$0.00	$0.00	$0.00
Cost of Revenue	$100.00K	$0.00	—	—
Gross Profit	$900.00K	$0.00	—	—
Research & Development	$20.27M	$24.01M	$19.10M	$16.02M
Selling, General & Admin	$12.58M	$13.86M	$12.42M	$12.25M
Operating Expenses	$32.85M	$37.87M	$31.51M	$28.27M
Operating Income	-$31.95M	-$37.87M	-$31.51M	-$28.27M
EBITDA	-$31.95M	-$37.87M	-$31.51M	-$28.27M
Pretax Income	-$41.30M	-$37.34M	-$30.88M	-$26.86M
Income Tax	$0.00	—	—	—
Net Income	-$41.30M	-$37.34M	-$30.88M	-$26.86M
Diluted EPS	-2.13	-1.34	-0.50	-0.25
Diluted Shares	19.40M	27.78M	61.20M	109.05M

SLS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.13M	$2.53M	$13.89M	$71.79M
Current Assets	$17.76M	$3.17M	$16.33M	$75.21M
Total Assets	$20.94M	$6.22M	$19.43M	$78.34M
Current Liabilities	$15.52M	$13.73M	$9.51M	$7.02M
Total Debt	$945.00K	$906.00K	$1.00M	$1.00M
Total Liabilities	$16.09M	$14.20M	$9.97M	$7.47M
Retained Earnings	-$179.90M	-$217.24M	-$248.13M	-$274.99M
Shareholders' Equity	$4.85M	-$7.98M	$9.46M	$70.87M
Working Capital	$2.24M	-$10.56M	$6.82M	$68.19M

SLS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.81M	-$31.41M	-$35.40M	-$28.39M
Capital Expenditure	-$4.50M	-$5.50M	—	—
Free Cash Flow	-$28.31M	-$36.91M	-$35.40M	-$28.39M
Stock-Based Compensation	$1.73M	$2.09M	$1.56M	$1.96M
Investing Cash Flow	-$4.50M	-$5.50M	$0.00	—
Financing Cash Flow	$24.08M	$22.32M	$46.76M	$86.30M
Net Change in Cash	-$4.23M	-$14.60M	$11.36M	$57.91M

SLS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.21M	$3.87M	$4.22M	$4.73M	$5.13M	$6.27M
Selling, General & Admin	$2.86M	$3.00M	$2.87M	$3.52M	$4.12M	$4.36M
Operating Expenses	$6.06M	$6.87M	$7.08M	$8.26M	$9.25M	$10.63M
Operating Income	-$6.06M	-$6.87M	-$7.08M	-$8.26M	-$9.25M	-$10.63M
EBITDA	-$6.06M	-$6.87M	-$7.08M	-$8.26M	-$9.25M	-$10.63M
Pretax Income	-$5.81M	-$6.60M	-$6.79M	-$7.66M	-$8.41M	-$9.61M
Net Income	-$5.81M	-$6.60M	-$6.79M	-$7.66M	-$8.41M	-$9.61M
Diluted EPS	-0.07	-0.07	-0.06	—	-0.05	-0.05
Diluted Shares	87.76M	98.56M	108.40M	—	172.48M	189.18M

SLS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$28.40M	$25.30M	$44.32M	$71.79M	$107.10M	$138.34M
Current Assets	$31.97M	$29.45M	$49.05M	$75.21M	$111.17M	$142.50M
Total Assets	$34.96M	$32.30M	$51.55M	$78.34M	$114.18M	$145.38M
Current Liabilities	$6.89M	$6.00M	$5.92M	$7.02M	$6.46M	$7.57M
Total Debt	$870.00K	$737.00K	$599.00K	$1.00M	$871.00K	$737.00K
Total Liabilities	$7.20M	$6.16M	$5.92M	$7.47M	$6.76M	$7.73M
Retained Earnings	-$253.94M	-$260.54M	-$267.33M	-$274.99M	-$283.39M	-$293.00M
Shareholders' Equity	$27.76M	$26.15M	$45.63M	$70.87M	$107.41M	$137.66M
Working Capital	$25.09M	$23.45M	$43.13M	$68.19M	$104.71M	$134.94M

SLS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$9.07M	-$7.33M	-$7.07M	-$4.92M	-$8.85M	-$7.59M
Free Cash Flow	-$9.07M	-$7.33M	-$7.07M	-$4.92M	-$8.85M	-$7.59M
Stock-Based Compensation	$505.00K	$501.00K	$503.00K	$447.00K	$798.00K	$1.01M
Financing Cash Flow	$23.58M	$4.23M	$26.09M	$32.39M	$44.15M	$38.83M
Net Change in Cash	$14.51M	-$3.10M	$19.02M	$27.47M	$35.30M	$31.25M

Market Snapshot

About

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies. The company focuses on therapies targeting acute myeloid leukemia and other blood cancers. Its lead product candidate is galinpepimut-S, a cancer immunotherapy designed to stimulate immune responses against malignant cells.